Is Mitotane a chemotherapy drug or a targeted drug?

Mitotane/Mitotane is a drug used to treat adrenocortical cancer. Its mechanism of action is mainly achieved by inhibiting the function of adrenocortical cells and inducing apoptosis. Although mitotane is classified as a chemotherapy drug in some cases, its mechanism of action is different from traditional chemotherapy drugs. In clinical applications, mitotane is often used to treat patients with advanced adrenocortical cancer, especially those with residual disease or metastatic disease after surgery.

The chemical structure of mitotane is similar to that of some steroids and can interfere with the synthesis of adrenal hormones and cause selective toxicity to adrenal tissue. This drug can treat adrenal gland-related diseases by affecting hormone levels in the body. Although its uses are similar to those of chemotherapy drugs, mitotane is not a chemotherapy drug in the traditional sense because it does not primarily achieve therapeutic effects by directly inhibiting cells or attacking rapidly proliferating cells.

When using mitotane, doctors need to carefully monitor the patient's hormone levels and possible side effects, such as liver function abnormalities, gastrointestinal reactions, etc. In addition, mitotane may also have effects on other systems, such as the nervous system. Therefore, during the treatment process, medical staff usually adopt comprehensive management strategies to ensure patient safety and treatment effectiveness.

In short, mitotane is neither fully a traditional chemotherapy drug nor fully meets the definition of a targeted drug. It is more like a special endocrine therapy drug, mainly used to target specific types of tumors. Although its mechanism of action has some overlap with targeted drugs, mitotane is widely used in the treatment of adrenocortical cancer in clinical practice due to its unique biological activities and indications. For doctors, understanding mitotane's mechanism of action and its potential side effects is crucial to developing an individualized treatment plan.

Reference materials:https://www.cancerresearchuk.org/about-cancer/treatment/drugs/mitotane-lysodren